GlassScriptPhysician profile
Richard Sternberg
NPI 1356333470
$33,341.45
in general payments reported to CMS, 2019-2025
36 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $691 · 2021: $13K · 2022: $4,965 · 2023: $9,344 · 2024: $2,699 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,635 · Consulting Fee: $3,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,800 · Travel and Lodging: $482 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,635.39 |
| Consulting Fee | $3,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,800.00 |
| Travel and Lodging | $482.26 |
| Education | $173.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,312.71 | 2019-2025 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $2,124.34 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,431.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,325.87 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $699.84 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $546.79 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $545.76 | 2019-2024 | Yupelri |
| Genzyme Corporation | $423.77 | 2021-2025 | |
| United Therapeutics Corporation | $360.77 | 2021-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $225.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $225.00 | 2019-2020 | |
| Inogen, INC. | $197.62 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sunovion Pharmaceuticals INC. | $180.30 | 2019-2020 | |
| Pulmonx Corporation | $171.09 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Actelion Pharmaceuticals US, INC. | $154.74 | 2019-2024 | Opsumit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $141.12 | 2021-2024 | Glassia |
| Noah Medical Corporation | $134.07 | 2025 | Galaxy |
| Janssen Scientific Affairs, LLC | $129.60 | 2023 | Tremfya |
| Amarin Pharma, INC. | $116.07 | 2019 | |
| Insmed, INC. | $113.85 | 2021-2024 | Arikayce |
| Genentech USA, INC. | $108.87 | 2019-2024 | Xolair, Esbriet |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Viatris Specialty LLC | $86.32 | 2025 | Yupelri |
| Electromed, INC. | $70.58 | 2022-2024 | Smartvest |
| Philips North America LLC | $60.01 | 2022-2025 | Vest Therapy Und |
| Teva Pharmaceuticals USA, INC. | $56.16 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $52.64 | 2021-2023 | Belsomra |
| Novartis Pharmaceuticals Corporation | $47.49 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $36.94 | 2020-2022 | |
| Pfizer INC. | $34.13 | 2023-2024 | |
| Covis Pharma Gmbh | $31.68 | 2022-2023 | |
| Gilead Sciences, INC. | $27.07 | 2021 | |
| Vifor Pharma, INC. | $21.74 | 2025 | Zemaira |
| Harmony Biosciences LLC | $21.53 | 2022 | |
| Axsome Therapeutics, INC. | $13.40 | 2023 | Sunosi |
| Circassia INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sternberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.